Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Country/Region
  • No block ID is set

  • Clinic Portal
    • +0034963905310
  • Request Information
  • +34 96 390 53 10
  • Part of brands: |
InternationalInternational
  • Country/Region
  • Part of brands: |
  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
Genomics Precision Diagnostic > Metabolic Precision Panel > Urea Cycle Disorder Precision Panel

Urea Cycle Disorder Precision Panel

The Urea Cycle is the metabolic pathway that transforms nitrogen from peripheral (muscle) and enteral sources (protein ingestion) into urea that is water soluble and can be excreted. Deficiency of an enzyme in the pathway causes a urea cycle disorder (UCD). 
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • The Urea Cycle is the metabolic pathway that transforms nitrogen from peripheral (muscle) and enteral sources (protein ingestion) into urea that is water soluble and can be excreted. Deficiency of an enzyme in the pathway causes a urea cycle disorder (UCD). Examples of UCDs include carabmyl phosphate synthetase I deficiency, ornithine transcarbamylase deficiency or arginase deficiency amongst others. All UCDs except for arginase deficiency, result in hyperammonaemia and life-threatening metabolic decompensations in infancy. If the patient survives, there is usually a severe neurologic injury. The inheritance of the UCDs is autosomal recessive except for ornithine transcarbamylase (OTC) deficiency which is X-linked. 

  • The Igenomix Urea Cycle Disorder Precision Panel can be used to make an accurate and directed diagnosis ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.  

Indication

  • The Igenomix Urea Cycle Disorder Precision Panel is indicated for those patients with a clinical suspicion or diagnosis with or without the following manifestations during the newborn period: 
    • Decreased level of consciousness 
    • Altered mental status 
    • Abnormal motor function 
    • Seizures 
    • Vomiting 
    • Poor feeding 
    • Diarrhea 
    • Nausea 
    • Constipation 
    • Somnolence 
    • Inability to maintain body temperature 
    • Hyperammonemia and hyperventilation 
    • Lethargy 
    • Coma 

Clinical Utility

The clinical utility of this panel is: 

  • The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient.  
  • Early initiation in the form of rehydration and maintenance of good urine output without overhydration, remove nitrogen (ammonia) from the body with medications and/or haemodialysis, decrease protein intake and minimize catabolism, stimulate anabolism and uptake of nitrogen precursors by muscle.  
  • Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance. 
  • Improvement of delineation of genotype-phenotype correlation. 

Genes & Diseases

Methodology

References

See scientific referrals

Mew, N., Simpson, K., Gropman, A., Lanpher, B., Chapman, K., & Summar, M. (2021). Urea Cycle Disorders Overview. Retrieved 5 April 2021, from http://www.ncbi.nlm.nih.gov/books/NBK1217 

Batshaw ML, Tuchman M, Summar M, et al. A longitudinal study of urea cycle disorders. Mol Genet Metab 2014; 113:127. 

Leonard, J., & Morris, A. (2002). Urea cycle disorders. Seminars In Neonatology, 7(1), 27-35. doi: 10.1053/siny.2001.0085 

Matsumoto, S., Häberle, J., Kido, J., Mitsubuchi, H., Endo, F., & Nakamura, K. (2019). Urea cycle disorders-update. Journal of human genetics, 64(9), 833–847. https://doi.org/10.1038/s10038-019-0614-4 

Häberle, J., Burlina, A., Chakrapani, A., Dixon, M., Karall, D., Lindner, M., Mandel, H., Martinelli, D., Pintos-Morell, G., Santer, R., Skouma, A., Servais, A., Tal, G., Rubio, V., Huemer, M., & Dionisi-Vici, C. (2019). Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision. Journal of inherited metabolic disease, 42(6), 1192–1230. https://doi.org/10.1002/jimd.12100 

Lilliu, F. (2010). Treatment of organic acidurias and urea cycle disorders. The Journal Of Maternal-Fetal & Neonatal Medicine, 23(sup3), 73-75. doi: 10.3109/14767058.2010.509932 

descargar

Detail description

Download

Request Information

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

OUR SERVICES

Genetic testing solutions
For patients
How to send a sample?
User manual

ABOUT US

About Igenomix
Contact
Quality
Complaints
Work with us
Terms and conditions

FOLLOW IGENOMIX

  + 96 390 53 10
  Write us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Country/Region

[2024] © Igenomix Privacy Page Quality policy Legal note Cookies policy

Request Information


  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
  • Country/Region
  • +34 96 390 53 10
  • Clinic Portal
  • Request Information